Excelsior Biopharma Inc. (TPEX:6496)

Excelsior Biopharma Revenue

Excelsior Biopharma had revenue of 230.11M TWD in the quarter ending September 30, 2026, with 11.09% growth. This brings the company's total for the last twelve months to 959.88M, up 11.64% year-over-year. In the year 2025, Excelsior Biopharma had annual revenue of 898.26M with 4.22% growth. That makes Excelsior Biopharma the 31,544th largest company in the world by revenue and 1,596th in Taiwan.

• Revenue (ttm): 959.88M
• Revenue Growth: +11.64%
• P/S Ratio: 1.16
• Revenue / Employee: n/a
• Employees: n/a
• Market Cap: 1.11B

Revenue Chart

Chart

Chart

Revenue by Geography

Chart

• Taiwan 861.23M 95.9%
• China 35.99M 4.0%
• Others 1.05M 0.1%

Fiscal year ended Dec 31, 2025 See the full Excelsior Biopharma breakdown

Revenue History

Fiscal Year End	Revenue	Change	Growth
Dec 31, 2025	898.26M	36.35M	4.22%
Dec 31, 2024	861.91M	90.35M	11.71%
Dec 31, 2023	771.56M	99.80M	14.86%
Dec 31, 2022	671.76M	-666.63M	-49.81%
Dec 31, 2021	1.34B	-105.27M	-7.29%

Data Source: S&P Global Market Intelligence Last updated: Nov 2, 2026

Revenue data is provided by S&P Global Market Intelligence and updates within hours after each earnings release, which is every three months for this company.

Update frequency:

Quarterly

Last checked:

Nov 7, 2026

Data Sources Report a data error